Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by D.B. Root & Company LLC

D.B. Root & Company LLC raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 27.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 1,109 shares of the pharmaceutical company’s stock after buying an additional 242 shares during the quarter. D.B. Root & Company LLC’s holdings in Vertex Pharmaceuticals were worth $538,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd lifted its stake in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares during the period. Mascagni Wealth Management Inc. acquired a new stake in Vertex Pharmaceuticals during the 4th quarter valued at approximately $31,000. SJS Investment Consulting Inc. lifted its stake in Vertex Pharmaceuticals by 46.2% during the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock valued at $46,000 after acquiring an additional 30 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in Vertex Pharmaceuticals during the 1st quarter valued at approximately $46,000. Finally, Stone House Investment Management LLC acquired a new stake in Vertex Pharmaceuticals during the 1st quarter valued at approximately $48,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Up 0.8%

Vertex Pharmaceuticals stock opened at $397.46 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The firm has a market capitalization of $101.90 billion, a price-to-earnings ratio of 28.41 and a beta of 0.44. The company has a fifty day simple moving average of $440.20 and a 200-day simple moving average of $462.13.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the prior year, the firm earned ($12.83) earnings per share. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Activity

In other news, Director Bruce I. Sachs acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the subject of several analyst reports. Stifel Nicolaus decreased their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a research note on Tuesday, August 5th. Scotiabank decreased their target price on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 5th. The Goldman Sachs Group reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. UBS Group set a $553.00 target price on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 5th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a research note on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $497.10.

View Our Latest Analysis on VRTX

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Articles

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.